Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma

Metastatic Malignant Melanoma Clinical Trial

Official title:
Phase I/II Trial for Vaccine Therapy With Dendritic Cells - Transfected With hTERT-, Survivin- and Tumor Cell Derived mRNA + ex Vivo T Cell Expansion and Reinfusion in Patients With Metastatic Malignant Melanoma

Status Terminated

Clinical Trial Summary

In this trial the investigators want to combine chemotherapy with immunotherapy by giving the patients Temozolomide, before vaccination. The investigators have also included hTERT and survivin mRNA in the vaccine. Finally, the investigators want to introduce ex vivo T cell expansion after lymphodepletion for the patients who show an immune response.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00961844
Study type	Interventional
Source	Oslo University Hospital
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	August 2009
Completion date	June 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00533702` - A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma	Phase 2
Active, not recruiting	`NCT02617849` - Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma	Phase 2
Terminated	`NCT00304200` - Temodar and Sutent as Therapy for Melanoma	Phase 1/Phase 2
Completed	`NCT01654692` - A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma	Phase 2
Completed	`NCT02350972` - Inducing Systemic Immunity and Regressions in Metastatic Melanoma	Phase 1
Terminated	`NCT01705392` - Bevacizumab vs Dacarbazine in Metastatic Melanoma	Phase 2
Completed	`NCT00625768` - Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma	Phase 1
Completed	`NCT00462423` - Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study	Phase 2